Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Physiologic Effects of Inhaled NO and Nitroglycerin in Sickle Cell Anemia
NCT00001716Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Jul 1998
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised trial of nitric oxide and nitroglycerin in sickle cell anemia (SCA) (2 cohorts), sponsored by National Institutes of Health. Primary endpoints: Microvascular perfusion, Hemoglobin oxygen affinity and 3 more. Started Jul 1998; status: completed.
02
Drugs
nitric oxidenitroglycerin
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT00001716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001716.